Status:

TERMINATED

Effectiveness Study of the Ivivi SofPulse for Pain Amelioration in Adults With Mild to Moderate Knee Osteoarthritis

Lead Sponsor:

Amp Orthopedics, Inc.

Conditions:

Knee Osteoarthritis

Eligibility:

All Genders

40-80 years

Phase:

PHASE4

Brief Summary

The purpose of this study is to determine the effectiveness of non-thermal Pulsed Radio Frequency (PRF) treatment with the Ivivi SofPulse for amelioration of knee pain in patients with mild to moderat...

Detailed Description

This prospective, double-blind, randomized, sham-controlled clinical trial will investigate the effectiveness of PRF using the Ivivi SofPulse on knee pain severity in adults with mild to moderate knee...

Eligibility Criteria

Inclusion

  • Age 40 to 80 years
  • Bilateral weight-bearing anteroposterior x-ray of each knee taken within the last 12 months and radiographs submitted to the Principal Investigator for evaluation
  • Radiographic evidence of mild to moderate (Kellgren/Lawrence grade 2 or 3) OA in at least one knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
  • Self-reported persistent knee pain severity of 4.0 to 8.0 cm on a 10 cm VAS for most days in the previous 2 months in at least one knee, with grade 2 or 3 OA
  • Able to read and complete English-language surveys
  • Daily access to the internet
  • Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects
  • Consent to the study and willing to comply with study methods

Exclusion

  • Subjects who have any implanted metallic leads, wires, or systems (e.g. pacemaker, implantable cardioverterdefibrillator)
  • Self-reported persistent knee pain severity \> 8.0 cm on a 10 cm VAS in either knee for most days in the previous 2 months
  • Radiographic evidence of severe (Kellgren/Lawrence grade 4) OA in either knee based on a weight-bearing anteroposterior x-ray taken within the last 12 months
  • Self-reported diagnosis of autoimmune or inflammatory arthritis (e.g. Rheumatoid Arthritis, Lupus, etc.)
  • More than 8 days of narcotic pain medication in the last 30 days
  • Joint surgery, tidal lavage, or arthroscopy of either knee in the past 6 months
  • Intra-articular corticosteroid or hyaluronic acid injections of either knee in the past 6 months
  • Oral prednisone use in the past 30 days
  • Participation in any clinical trial in the past 30 days
  • Knee OA associated with worker's compensation or accident litigation
  • Regular use of a walker or wheelchair
  • Vulnerable populations including prisoners and nursing home residents
  • Anticipated move away from immediate area in next 6 months
  • Any medical condition that, in the opinion of the investigator, may compromise patient safety or confound the assessment of treatment effectiveness
  • After 1-week Run-in Period
  • Daily average of "current" knee pain severity \< 4.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in both knees
  • Daily average of "current" knee pain severity \> 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in either knee
  • Daily average of "current" knee pain severity of 4.0 to 8.0 cm, assessed on a 10 cm VAS, during the 1-week run-in period in any knee with Kellgren/Lawrence grades of 0 or 1 in the same knees
  • Narcotic use of more than 2 days during the 1-week runin period
  • Noncompliance with online symptom reporting requirements

Key Trial Info

Start Date :

October 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2012

Estimated Enrollment :

45 Patients enrolled

Trial Details

Trial ID

NCT01457742

Start Date

October 1 2011

End Date

July 1 2012

Last Update

July 10 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mytrus, Inc.

San Francisco, California, United States, 94104